NCT04722523 2026-03-30
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
Clinical Trials
66 trialsNCT02215720 2026-03-20
TORERO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT05985954 2026-03-12
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05722327 2026-03-04
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04290546 2026-02-27
CIML NK Cell in Head & Neck Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT07217028 2026-02-27
Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma
Vanderbilt-Ingram Cancer Center
Phase 1 Not yet recruiting
NCT05040568 2026-01-26
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT06358430 2026-01-15
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03290937 2026-01-06
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT06447987 2025-12-17
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
City of Hope Medical Center
Phase 1 Recruiting
NCT06912087 2025-12-02
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
University of Chicago
Phase 1 Recruiting
NCT01552434 2025-10-14
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT01787500 2025-09-09
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06005324 2025-06-08
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
University of Chicago
Phase 1 Recruiting
NCT03524326 2025-05-13
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03498378 2025-04-03
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of California, San Diego
Phase 1 Active not recruiting
NCT04091867 2025-02-24
sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC
University of Colorado, Denver
Phase 1 Completed
NCT03667482 2024-07-23
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT06225622 2024-03-19
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
Phase 1 Recruiting
NCT06067776 2023-10-05
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
University of California, Davis
Phase 1 Not yet recruiting
NCT00593060 2023-05-24
Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT02764593 2022-11-29
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
RTOG Foundation, Inc.
Phase 1 Completed
NCT05155124 2022-09-13
Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT05019534 2022-05-19
Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
West China Hospital
Phase 1 Unknown
NCT02438995 2021-11-03
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Northwell Health
Phase 1 Terminated
NCT02282371 2021-10-26
Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02095054 2021-04-01
Regorafenib and Cetuximab in Patients With Advanced Malignancy
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00543504 2020-06-30
Bevacizumab in Multiple Phase I Combinations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01621217 2020-02-28
NOAC8
Lund University Hospital
Phase 1 Completed
NCT02938273 2019-12-11
Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)
The Netherlands Cancer Institute
Phase 1 Completed
NCT01758731 2019-09-23
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
University of Colorado, Denver
Phase 1 Completed
NCT00501410 2019-08-28
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02277197 2019-04-18
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Pittsburgh
Phase 1 Completed
NCT01716416 2019-04-16
HNSCC
Washington University School of Medicine
Phase 1 Completed
NCT01871311 2019-02-08
A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
Georgetown University
Phase 1 Terminated
NCT00882583 2019-01-09
Dasatinib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT01540682 2018-08-29
MLN8237 in Head and Neck Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00622674 2017-12-02
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT02630420 2017-10-26
Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer
Yale University
Phase 1 Withdrawn
NCT01238237 2017-02-01
Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA
Northwell Health
Phase 1 Completed
NCT00477880 2017-01-10
Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer
Vanderbilt University Medical Center
Phase 1 Completed
NCT02573220 2016-12-09
Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
University of Chicago
Phase 1 Withdrawn
NCT00736619 2016-08-10
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02845999 2016-07-27
NK-EGFR01
Centre Hospitalier Universitaire de Besancon
Phase 1 Completed
NCT00940381 2015-11-18
Sirolimus and Cetuximab in Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00941499 2015-11-18
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00980239 2015-11-11
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00895362 2015-07-13
Erlotinib in Combination With Cetuximab
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01294826 2015-06-08
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Swedish Medical Center
Phase 1 Completed
NCT00388427 2015-05-28
Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies
University of Pittsburgh
Phase 1 Completed